By Lisa Kerner
Erie, Pa., March 9 - AxoGen, Inc. said it closed a $7.75 million series B financing round.
Proceeds will be used to finance the development of a human allograph for peripheral nerve repair and regeneration.
The round was led by a consortium including Cardinal Partners, Accuitive Medical Ventures and De Novo Ventures.
Lisa Skeete Tatum, general partner at Cardinal, Gerard Van Hamel Platerink, managing director at Accuitive, and Joe Mandato, managing director at De Novo Ventures, will join AxoGen's board of directors.
Located in Gainesville, Fla., AxoGen commercializes technology developed at the McKnight Brain Institute of the University of Florida.
| Issuer: | AxoGen, Inc.
|
| Issue: | Series B financing
|
| Amount: | $7.75 million
|
| Investors: | Cardinal Partners, Accuitive Medical Ventures, De Novo Ventures
|
| Announcement date: | March 9
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
